NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7Metastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT02520778
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2018-09-25
- Target Recruit Count
- 22
- Registration Number
- NCT02511431
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Non-Cutaneous MelanomaRecurrent Cutaneous MelanomaRecurrent Mucosal MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Metastatic Cutaneous MelanomaMetastatic Mucosal MelanomaRecurrent Non-Cutaneous MelanomaNon-Cutaneous Melanoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Quality-of-Life Assessment
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1301
- Registration Number
- NCT02506153
- Locations
- 🇺🇸
Ephrata Cancer Center, Ephrata, Pennsylvania, United States
🇺🇸Ephrata Community Hospital, Ephrata, Pennsylvania, United States
🇺🇸UPMC Hillman Cancer Center Erie, Erie, Pennsylvania, United States
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT02504892
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7Stage III Lung Non-Small Cell Cancer AJCC v7Recurrent Lung Non-Small Cell CarcinomaStage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT02503722
- Locations
- 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇨🇦BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Metastatic Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmUnresectable Solid Neoplasm
- Interventions
- Drug: CDK Inhibitor AT7519Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT02503709
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
- Conditions
- Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell Carcinoma
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire Administration
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 582
- Registration Number
- NCT02502266
- Locations
- 🇺🇸
Sutter Roseville Medical Center, Roseville, California, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
- Conditions
- Locally Advanced Bone SarcomaMetastatic LiposarcomaLocally Advanced Gastrointestinal Stromal TumorPleomorphic LiposarcomaStage III Soft Tissue Sarcoma AJCC v7Locally Advanced Dedifferentiated LiposarcomaLocally Advanced Soft Tissue SarcomaMetastatic Unresectable SarcomaUnresectable LiposarcomaMetastatic Soft Tissue Sarcoma
- Interventions
- Biological: IpilimumabOther: Laboratory Biomarker AnalysisBiological: NivolumabOther: Quality-of-Life Assessment
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 164
- Registration Number
- NCT02500797
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Recurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT02498600
- Locations
- 🇺🇸
Mercy Medical Center, Durango, Colorado, United States
🇺🇸Southwest Oncology PC, Durango, Colorado, United States
🇺🇸Rose Medical Center, Denver, Colorado, United States
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
- Conditions
- Advanced Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaMetastatic Triple-Negative Breast CarcinomaStage III Breast Cancer AJCC v7Stage III Lung Small Cell Carcinoma AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Stage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7Triple-Negative Breast Carcinoma
- Interventions
- Other: 18F-FluoromisonidazoleOther: Laboratory Biomarker AnalysisProcedure: Positron Emission Tomography
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 122
- Registration Number
- NCT02498613
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States